UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. 1)
Filed by the Registrant ☒
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
☒ Definitive Additional Materials
Soliciting Material under Rule 14a-12
TETRA TECHNOLOGIES, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
Payment of Filing Fee (Check all boxes that apply):
☒ | No fee required |
☐ | Fee paid previously with preliminary materials |
☐ | Check Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
This Amendment No. 1 to Schedule 14A (this “Amendment”) is being filed to amend TETRA Technologies Inc.’s (the “Company”) definitive proxy statement (the “Proxy Statement”) for its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), which was filed with the Securities and Exchange Commission on April 11, 2023. This Amendment amends Proposal No. 4 (Approval of our Second Amended and Restated 2018 Equity Incentive Plan) of the Proxy Statement, which includes a summary of the principal terms of the First Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”) and requests approval of the Company’s Second Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”) in order to increase the number of shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), available for issuance under the 2018 Plan by 4,500,000 shares.
In Proposal No. 4 of the Proxy Statement, the Company made statements regarding the factors considered in setting the number of additional shares of Common Stock requested for reservation under the Amended 2018 Plan, including the number of shares of Common Stock remaining available for issuance under the 2018 Plan as of the close of business on each of December 31, 2022 and March 27, 2023.
The Company wishes to expand its disclosure in Proposal No. 4 to reiterate the number of awards outstanding and the shares available for grant under the 2018 Plan. To clarify certain matters described in the Proxy Statement:
This Amendment hereby removes the table identified in the preceding sentence included in the Proxy Statement and replaces it with the table below. The narrative associated with the below table contained in the Proxy Statement is correct and as such has not been included in this Amendment.
Shares available for grant and outstanding awards
To facilitate approval of the Amended 2018 Plan, we are providing updated information as of our record date, March 27, 2023. As of the close of business on March 27, 2023, there were 129,353,856 shares of our common stock issued and outstanding. The closing sale price of a share of our common stock on the New York Stock Exchange on that date was $2.61. The following table summarizes information regarding awards outstanding and shares remaining available for grant under the 2018 Plan, the 2011 Plan, the 2007 Plan and under the Inducement Plan, as of the close of business on March 27, 2023:
2018 Plan | All Other Plans | Inducement Plan | ||||||||
Total shares underlying outstanding stock options | 16,618 | 2,554,129 | __ | |||||||
Weighted average exercise price of outstanding stock options | $ 4.19 | $ 6.51 | __ | |||||||
Weighted average remaining duration (years) of outstanding stock options | 5.18 | 3.10 | __ | |||||||
Total shares underlying outstanding unvested restricted stock units |
| 4,251,564 |
|
| __ |
|
|
| __ |
|
Total shares underlying outstanding unvested time-based restricted stock awards | __ | __ | __ | |||||||
Total shares available for grant | 1,558,195 | __ | 76,495 | |||||||
